Paclitaxel delivery to brain tumors from hydrogels: A computational study

Biotechnology Progress

Volumn 27, Issue 5, 2011, Pages 1478-1487

  Torres, Alexis J ^a   Zhu, Charles ^a   Shuler, Michael L ^a   Pannullo, Susan ^b  

^a Cornell University   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Brain tumors; Controlled release; Hydrogel; OncoGel; Paclitaxel

Indexed keywords

BRAIN TISSUE; BRAIN TUMORS; CARMUSTINE; COMPUTATIONAL STUDIES; CONTROLLED RELEASE; DRUG CONCENTRATION; HYDROPHOBIC DRUG; ONCOGEL; PACLITAXEL; PACLITAXEL DELIVERY; PHARMACOLOGICAL AGENTS; POLYMER CARRIER; SURFACE AREA; SUSTAINED RELEASE; VOLUME RATIO;

DRUG THERAPY; TUMORS;

HYDROGELS;

ANTINEOPLASTIC AGENT; DRUG CARRIER; PACLITAXEL;

ANIMAL; ARTICLE; BRAIN TUMOR; HUMAN; HYDROGEL; METABOLISM; MOUSE; THEORETICAL MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; DRUG CARRIERS; HUMANS; HYDROGELS; MICE; MODELS, THEORETICAL; PACLITAXEL;

EID: 80053906706     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.665     Document Type: Article

References (43)

1. Laws ERJr, Thapar K. Brain tumors. CA Cancer J Clin. 1993; 43: 263-271.
2. Attenello F, Mukherjee D, Datoo G, McGirt M, Bohan E, Weingart J, Olivi A, Quinones-Hinojosa A, Brem H. Use of gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Anna Surg Oncol. 2008; 15: 2887-2893.
3. McGirt M, Brem H. Carmustine wafers (Gliadel) plus concomitant temozolomide therapy after resection of malignant astrocytoma: growing evidence for safety and efficacy. Annal Surg Oncol. 2010; 17: 1729-1731.
4. Donelli MG, Zucchetti M, D'Incalci M. Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol. 1992; 30: 251-260.
5. Deeken JF, Löscher W. The blood-brain barrier and cancer: transporters, treatment, and trojan horses. Clin Cancer Res. 2007; 13: 1663-1674.
6. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 1995; 345: 1008-1012.
7. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncol. 2003; 5: 79-88.
8. Kanter PM, Schwartz HS, West CR. Functional and chemical markers of PCNU Activity. Cancer Drug Deliv. 1983; 1: 11-20.
9. Loo TL, Dion RL, Dixon RL, Rall DP. The antitumor agent, 1, 3-bis(2-chloroethyl)-1-nitrosourea. J Pharm Sci. 1966; 55: 492-497.
10. Fung LK, Ewend MG, Sills A, Sipos EP, Thompson R, Watts M, Michael Colvin O, Brem H, Saltzman WM. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res. 1998; 58: 672-684.
11. Giese A, Westphal M. Glioma invasion in the central nervous system. Neurosurgery. 1996; 39: 235-252.
12. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology. 1980; 30: 907-911.
13. Li KW, Dang W, Tyler BM, Troiano G, Tihan T, Brem H, Walter KA. Polilactofate microspheres for paclitaxel delivery to central nervous system malignancies. Clin Cancer Res. 2003; 9: 3441-3447.
14. Ranganath SH, Fu Y, Arifin DY, Kee I, Zheng L, Lee H-S, Chow PKH, Wang C-H. The use of submicron/nanoscale PLGA implants to deliver paclitaxel with enhanced pharmacokinetics and therapeutic efficacy in intracranial glioblastoma in mice. Biomaterials. 2010; 31: 5199-5207.
15. Ong BYS, Ranganath SH, Lee LY, Lu F, Lee H-S, Sahinidis NV, Wang C-H. Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme. Biomaterials. 2009; 30: 3189-3196.
16. Ranganath SH, Wang C-H. Biodegradable microfiber implants delivering paclitaxel for post-surgical chemotherapy against malignant glioma. Biomaterials. 2008; 29: 2996-3003.
17. Xie J, Wang C-H. Electrospun Micro- and Nanofibers for Sustained Delivery of Paclitaxel to Treat C6 Glioma in vitro. Pharm Res. 2006; 23: 1817-1826.
18. Tyler B, Fowers KD, Li KW, Recinos VR, Caplan JM, Hdeib A, Grossman R, Basaldella L, Bekelis K, Pradilla G, Legnani F, Brem H. A thermal gel depot for local delivery of paclitaxel to treat experimental brain tumors in rats. J Neurosurg. 2010; 113: 210-217.
19. Ke X-Y, Zhao B-J, Zhao X, Wang Y, Huang Y, Chen X-M, Zhao B-X, Zhao S-S, Zhang X, Zhang Q. The therapeutic efficacy of conjugated linoleic acid - Paclitaxel on glioma in the rat. Biomaterials. 2010; 31: 5855-5864.
20. Eckardstein KLv, Patt S, Kratzel C, Kiwit JCW, Reszka R. Local chemotherapy of F98 rat glioblastoma with paclitaxel and carboplatin embedded in liquid crystalline cubic phases. J Neuro-Oncol. 2005; 72: 209-215.
21. Ranganath S, Kee I, Krantz W, Chow P, Wang C-H. Hydrogel matrix entrapping PLGA-paclitaxel microspheres: drug delivery with near zero-order release and implantability advantages for malignant brain tumour chemotherapy. Pharm Res. 2009; 26: 2101-2114.
22. Cahan MA, Walter KA, Colvin OM, Brem H. Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol. 1994; 33: 441-444.
23. Walter KA, Cahan MA, Gur A, Tyler B, Hilton J, Colvin OM, Burger PC, Domb A, Brem, H. Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res. 1994; 54: 2207-2212.
24. Ozeki T, Hashizawa K, Kaneko D, Imai Y, Okada H. Treatment of rat brain tumors using sustained-release of camptothecin from poly(lactic-co-glycolic acid) microspheres in a thermoreversible hydrogel. Chem Pharm Bull. 2010; 58: 1142-1147.
25. Akbar U, Jones T, Winestone J, Michael M, Shukla A, Sun Y, Duntsch C. Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection. J Neuro-Oncol. 2009; 94: 203-212.
26. Arai T, Joki T, Akiyama M, Agawa M, Mori Y, Yoshioka H, Abe T. Novel drug delivery system using thermoreversible gelation polymer for malignant glioma. J Neuro-Oncol. 2006; 77: 9-15.
27. Kim S, Nishimoto SK, Bumgardner JD, Haggard WO, Gaber MW, Yang Y. A chitosan/beta-glycerophosphate thermo-sensitive gel for the delivery of ellagic acid for the treatment of brain cancer. Biomaterials. 2010; 31: 4157-4166.
28. Loh XJ, Li J. Biodegradable thermosensitive copolymer hydrogels for drug delivery. Exp Opin Ther Pat. 2007; 17: 965-977.
29. Zentner GM, Rathi R, Shih C, McRea JC, Seo M-H, Oh H, Rhee BG, Mestecky J, Moldoveanu Z, Morgan M, Weitman S. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release. 2001; 72: 203-215.
30. Elstad NL, Fowers KD. OncoGel (ReGel/paclitaxel)-clinical applications for a novel paclitaxel delivery system. Adv Drug Deliv Rev. 2009; 61: 785-794.
31. Wang C-H, Li J, Teo CS, Lee T. The delivery of BCNU to brain tumors. J Control Release. 1999; 61: 21-41.
32. Arifin DY, Lee KYT, Wang C-H. Chemotherapeutic drug transport to brain tumor. J Control Release. 2009; 137: 203-210.
33. Arifin D, Lee K, Wang C-H, Smith K. Role of convective flow in carmustine delivery to a brain tumor. Pharm Res. 2009; 26: 2289-2302.
34. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res. 1989; 37: 77-104.
35. Fung LK, Shin M, Tyler B, Brem H, Saltzman WM. Chemotherapeutic drugs released from polymers: distribution of 1, 3-bis(2-chloroethyl)-l-nitrosourea in the rat brain. Pharm Res. 1996; 13: 671-682.
36. Wang C-H, Li J. Three-dimensional simulation of IgG delivery to tumors. Chem Eng Sci. 1998; 53: 3579-3600.
37. Kimelberg HK. Water homeostasis in the brain: basic concepts. Neuroscience. 2004; 129: 851-860.
38. Tan WHK, Lee T, Wang CH. Simulation of intratumoral release of etanidazole: effects of the size of surgical opening. J Pharm Sci. 2003; 92: 773-789.
39. Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet. 2002; 41: 403-419.
40. Liggins RT, Hunter WL, Burt HM. Solid-state characterization of paclitaxel. J Pharm Sci. 1997; 86: 1458-1463.
41. Xu L, Wu F, Yuan W, Jin T. Controlled-release implant system formulated using biodegradable hemostatic gauze as scaffold. Int J Pharm. 2008; 355: 249-258.
42. Dey S, Spring PM, Arnold S, Valentino J, Chendil D, Regine WF, Mohiuddin M, Ahmed MM. Low-dose fractionated radiation potentiates the effects of paclitaxel in wild-type and mutant p53 head and neck tumor cell lines. Clin Cancer Res. 2003; 9: 1557-1565.
43. Linninger AA, Somayaji MR, Mekarski M, Zhang L. Prediction of convection-enhanced drug delivery to the human brain. J Theor Biol. 2008; 250: 125-138.